• If you are wondering whether Cardinal Health at around US$200.55 is still reasonably priced or starting to look stretched, the valuation story is where your attention should go.
• Recent returns are mixed, with the share price down 5.3% over the last week and 2.8% over the last month, while still showing a 50.9% return over 1 year, 162.1% over 3 years and 274.6% over 5 years.
• These moves have come as Cardinal Health remains a widely followed healthcare distributor, with ongoing interest in its role in medical and pharmaceutical supply chains. Headlines around the sector and investor positioning in defensive healthcare names help frame the current share price swings.
• Right now, Cardinal Health scores a 4/6 valuation check result. This sets up a closer look at how different methods assess its price today and points to an even richer way of thinking about valuation that will come later in this article.

Approach 1: Cardinal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects the cash Cardinal Health could generate in the future, then discounts those cash flows back to today to estimate what the business might be worth right now.

Cardinal Health currently reports last twelve month Free Cash Flow of about $5.52b. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolations feed in annual cash flow projections, including an estimated $4.75b in Free Cash Flow by 2030. Beyond the explicit analyst horizon, Simply Wall St extends the projections further out to 2035 using gradual growth assumptions, then discounts each of those future cash flows back to today.

On this basis, the DCF model suggests an intrinsic value of about $525.18 per share, which compares to the recent share price of around $200.55. That gap implies a 61.8% discount, so the stock screens as materially undervalued using this method alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cardinal Health is undervalued by 61.8%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Approach 2: Cardinal Health Price vs Earnings

For a profitable company like Cardinal Health, the P/E ratio is a straightforward way to relate what you pay per share to the earnings the business is currently generating. Investors generally accept that higher growth expectations or lower perceived risk can support a higher "normal" P/E, while slower growth or higher risk tend to align with a lower multiple.

Cardinal Health currently trades on a P/E of 28.40x. That sits above the Healthcare industry average of 23.32x and the peer average of 24.14x. On simple comparisons, the shares look more expensive than many sector peers.

Simply Wall St's Fair Ratio for Cardinal Health is 31.11x. This is a proprietary estimate of what P/E might be reasonable when factoring in earnings growth characteristics, profit margins, industry, market cap and risk profile. Because it blends these company specific drivers rather than just averaging peers, the Fair Ratio can give a more tailored gauge of what investors might be prepared to pay.

Comparing the current P/E of 28.40x with the Fair Ratio of 31.11x suggests Cardinal Health is trading below that tailored benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Cardinal Health Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives let you attach a clear story about Cardinal Health to the numbers you care about by linking your view of its revenue, earnings and margin outlook to a financial forecast and fair value on Simply Wall St's Community page. You can then compare that fair value to the current share price to help you decide whether it looks attractive or stretched. Each Narrative updates when new information such as earnings or news arrives. One investor might lean toward the higher analyst fair value of US$275.00 based on confidence in specialty and home healthcare growth, while another might anchor closer to US$200.00 if more focused on regulation, competition and reimbursement risks.

Do you think there's more to the story for Cardinal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.